Loading…
Academic Journal
Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
Marion Larue, Myriam Labopin, Thomas Schroeder, Xiao‐jun Huang, Igor W. Blau, Johannes Schetelig, Arnold Ganser, Rose‐Marie Hamladji, Wolfgang Bethge, Nicolaus Kröger, Gerard Socié, Urpu Salmenniemi, Henrik Sengeloev, Bhagirathbhai Dholaria, Bipin N. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
HemaSphere, Vol 8, Iss 10, Pp n/a-n/a (2024)
Saved in:
| Title | Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia |
|---|---|
| Authors | Marion Larue, Myriam Labopin, Thomas Schroeder, Xiao‐jun Huang, Igor W. Blau, Johannes Schetelig, Arnold Ganser, Rose‐Marie Hamladji, Wolfgang Bethge, Nicolaus Kröger, Gerard Socié, Urpu Salmenniemi, Henrik Sengeloev, Bhagirathbhai Dholaria, Bipin N. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty |
| Publication Year |
2024
|
| Source |
HemaSphere, Vol 8, Iss 10, Pp n/a-n/a (2024)
|
| Description |
Abstract Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left‐truncated analysis of long‐term survival in patients with acute leukemia who were alive and disease‐free 2 years after HCT. We included 2701 patients with acute lymphoblastic leukemia (ALL) and 9027 patients with acute myeloid leukemia (AML) who underwent HCT between 2005 and 2012. The 10‐year overall survival (OS) rate was 81.3% for ALL and 76.2% for AML, with the main causes of late mortality being relapse (ALL‐33.9%, AML‐44.9%) and chronic graft‐versus‐host disease (ALL‐29%, AML‐18%). At 10 years, HCT‐related mortality was 16.8% and 20.4%, respectively. Older age and unrelated donor transplantation were associated with a worse prognosis for both types of leukemia. In addition, transplantation in the second or third complete remission and peripheral blood HSC for ALL are associated with worse outcomes. Similarly, adverse cytogenetics, female donor to male patient combination, and reduced intensity conditioning in AML contribute to poor prognosis. We conclude that 2‐year survival in remission after HCT for acute leukemia is encouraging, with OS of nearly 80% at 10 years. However, the long‐term mortality risk of HCT survivors remains significantly higher than that of the age‐matched general population. These findings underscore the importance of tailoring transplantation strategies to improve long‐term outcomes in patients with acute leukemia undergoing HCT.
|
| Document Type |
article
|
| Language |
English
|
| Publisher Information |
Wiley, 2024.
|
| Subject Terms | |
